Show simple item record

dc.contributor.authorAllan-Blitz, Lao-Tzu*
dc.contributor.authorHemarajata, Peera*
dc.contributor.authorHumphries, Romney M.*
dc.contributor.authorWynn, Adriane*
dc.contributor.authorSegura, Eddy R.*
dc.contributor.authorKlausner, Jeffrey D.*
dc.date.accessioned2018-02-12T14:44:00Z
dc.date.available2018-02-12T14:44:00Z
dc.date.issued2018-02
dc.identifier.citationA Cost Analysis of Gyrase A Testing and Targeted Ciprofloxacin Therapy Versus Recommended 2-Drug Therapy for Neisseria gonorrhoeae Infection 2018, 45 (2):87 Sexually Transmitted Diseaseses
dc.identifier.issn0148-5717
dc.identifier.doi10.1097/OLQ.0000000000000698
dc.identifier.urihttp://hdl.handle.net/10757/622635
dc.descriptionEl texto completo de este trabajo no está disponible en el Repositorio Académico UPC por restricciones de la casa editorial donde ha sido publicado.es
dc.description.abstractFrom the *Division of Infectious Diseases, Department of Medicine, †Department of Laboratory Medicine, David Geffen School of Medicine, Department of Medicine, ‡Fielding School of Public Health, University of California Los Angeles, Los Angeles, CA; §Escuela de Medicina, Universidad Peruana de Ciencias Aplicadas, Lima, Peru; and ¶Division of Infectious Diseases, Department of Medicine, University of California Los Angeles, Los Angeles, CA Conflict of Interest and Sources of Funding: None declared. This research was supported by the United States National Institutes of Health grants R21AI117256 and R21AI109005 as well as the South American Program in HIV Prevention Research NIH/NIMH R25MH087222. Correspondence: Lao-Tzu Allan-Blitz, MD Candidate, 2018, David Geffen School of Medicine, University of California Los Angeles, 10833 Le Conte Ave, Los Angeles, CA 90095. E‐mail: lallanblitz@mednet.ucla.edu. Received for publication February 21, 2017, and accepted July 30, 2017. DOI: 10.1097/OLQ.0000000000000698
dc.formatapplication/pdfes
dc.language.isoenges
dc.publisherLippincott Williams and Wilkinses
dc.relation.urlhttp://Insights.ovid.com/crossref?an=00007435-201802000-00004es
dc.rightsinfo:eu-repo/semantics/restrictedAccesses
dc.subjectAzithromycines
dc.subjectCeftriaxonees
dc.subjectCiprofloxacines
dc.subjectDNA topoisomerase (ATP hydrolysing) Aes
dc.subjectAntibiotic resistancees
dc.subjectAntibiotic sensitivityes
dc.subjectChlamydiasises
dc.subjectCost benefit analysises
dc.titleA Cost Analysis of Gyrase A Testing and Targeted Ciprofloxacin Therapy Versus Recommended 2-Drug Therapy for Neisseria gonorrhoeae Infectiones
dc.typeinfo:eu-repo/semantics/articlees
dc.identifier.journalSexually Transmitted Diseaseses
dc.description.fundingFrom the *Division of Infectious Diseases, Department of Medicine, †Department of Laboratory Medicine, David Geffen School of Medicine, Department of Medicine, ‡Fielding School of Public Health, University of California Los Angeles, Los Angeles, CA; §Escuela de Medicina, Universidad Peruana de Ciencias Aplicadas, Lima, Peru; and ¶Division of Infectious Diseases, Department of Medicine, University of California Los Angeles, Los Angeles, CA Conflict of Interest and Sources of Funding: None declared. This research was supported by the United States National Institutes of Health grants R21AI117256 and R21AI109005 as well as the South American Program in HIV Prevention Research NIH/NIMH R25MH087222. Correspondence: Lao-Tzu Allan-Blitz, MD Candidate, 2018, David Geffen School of Medicine, University of California Los Angeles, 10833 Le Conte Ave, Los Angeles, CA 90095es_PE
dc.description.peerreviewRevisión por pareses_PE
refterms.dateFOA2018-06-15T22:11:39Z
html.description.abstractFrom the *Division of Infectious Diseases, Department of Medicine, †Department of Laboratory Medicine, David Geffen School of Medicine, Department of Medicine, ‡Fielding School of Public Health, University of California Los Angeles, Los Angeles, CA; §Escuela de Medicina, Universidad Peruana de Ciencias Aplicadas, Lima, Peru; and ¶Division of Infectious Diseases, Department of Medicine, University of California Los Angeles, Los Angeles, CA Conflict of Interest and Sources of Funding: None declared. This research was supported by the United States National Institutes of Health grants R21AI117256 and R21AI109005 as well as the South American Program in HIV Prevention Research NIH/NIMH R25MH087222. Correspondence: Lao-Tzu Allan-Blitz, MD Candidate, 2018, David Geffen School of Medicine, University of California Los Angeles, 10833 Le Conte Ave, Los Angeles, CA 90095. E‐mail: lallanblitz@mednet.ucla.edu. Received for publication February 21, 2017, and accepted July 30, 2017. DOI: 10.1097/OLQ.0000000000000698


Files in this item

Thumbnail
Name:
10.1097 OLQ.0000000000000698.pdf
Size:
293.5Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record